Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 5, 2006, Pages 389-395

  Ekert, Henry ^a   Brizard, Christian ^a   Eyers, Robert ^a   Cochrane, Andrew ^a   Henning, Robert ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cardiopulmonary bypass; Congenital heart disease; Infant; Prophylaxis; Recombinant activated factor VII

Indexed keywords

FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; BLOOD VOLUME; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NEPHROTOXICITY; OPERATION DURATION; PARTIAL THROMBOPLASTIN TIME; PEDIATRIC SURGERY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCREENING TEST; THORAX; THROMBOCYTE COUNT; TREATMENT OUTCOME; WOUND CLOSURE;

ADOLESCENT; ADULT; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FACTOR VII; FACTOR VIIA; FEMALE; HEART DEFECTS, CONGENITAL; HEMOSTASIS; HEMOSTATICS; HUMANS; INFANT; INFANT, NEWBORN; MALE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33745431704     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000233369.03358.c1     Document Type: Article

References (16)

1. McCusker K, Lee S. Post cardiopulmonary bypass bleeding; an introductory review. J Extra-Corporeal Technol 1999; 31:23-26.
2. Manno CS, Hedberg KW, Kim HC, Bunnin GR, Nicolson S, Jobes D, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77:930-936.
3. Boldt J, Knothe C, Zickmann B, Wege N, Dapper F, Hempelmann G. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993; 55:1460-1466.
4. Guay J, Rivard GE. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg 1996; 62:1955-1960.
5. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1):S107-S111.
6. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002; 28:S248-S255.
7. Berstein D. Recombinant factor FVIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 1997; 113:1930-1937.
8. Girard P, Nony P, Erhardtsen E, Delair S, French P, Dechavanne M, Boissel JP. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost 1998; 80:109-113.
9. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4:790-798.
10. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII [see comment]. Anesth Analg 2001; 93:287-289.
11. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4:49-51.
12. Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor Vila to treat coagulation disturbances in pediatric patients. South Med J 2003; 96:12-16.
13. Zietkiewicz M, Garlicki M, Domagala J, Wierzbicki K, Drwila R, Pfitzner R. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002; 123:384-385.
14. Kastrup M, von Heymann C, Hotz H, Konertz WF, Ziemer S, Kox WJ. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002; 74:910-912.
15. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):S121-S127.
16. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55:638-648.